Kiadis Pharma has raised €23.4m of funding in a private placement of 2.6 million new shares, for developing a T-cell immunotherapy product to reduce Graft versus Host Disease (GVHD) in hematopoietic stem cell transplantations (HSCT).
Biogen has agreed to buy Pfizer's investigational schizophrenia drug, PF-04958242, in a deal worth about $590m.
LabCorp's Covance Drug Development business has established a global immunology and immunotoxicology (I&I) unit to focus on the development of biologic drugs.
Evotec and Sanofi are in exclusive negotiations to create an infectious disease open innovation research and development (R&D) platform through a new open innovation platform near Lyon in France.
Merck has formed an oncology collaboration with Eisai to jointly develop and commercialize the latter's Lenvima cancer treatment both as a monotherapy as well as in combination with its anti-PD-1 therapy, Keytruda, for various types of cancer.
Clinical stage biopharmaceutical firm JW Therapeutics has secured $90m Series A financing from a consortium led by Temasek, Sequoia Capital China, and YuanMing Capital.
Ligand Pharmaceuticals has signed a license agreement granting Roivant Sciences exclusive global rights to develop and commercialize its LGD-6972 glucagon receptor antagonist (GRA).
Caladrius Biosciences has acquired an exclusive worldwide license to data from Shire’s late stage CD34+ cell therapy program for the treatment of chronic myocardial ischemia targeting refractory angina.
Research into synthetic biology from the Universities of Warwick and Surrey has revealed that bacteria could be programmed to produce drugs.
Mylan said that it will launch two new HIV treatments, Symfi Lo and Cimduo, which have been approved in February this year by the US Food and Drug Administration (FDA).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.